Rapid identification of therapeutic targets in hematologic malignancies via functional genomics

Therapeutic Advances in Hematology

Volumn 2, Issue 2, 2011, Pages 83-93

  Tyner, Jeffrey W ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

deep sequencing; gene chip; neoplasia; personalized medicine; shRNA screen; siRNA screen

Indexed keywords

BCR ABL PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

CARCINOGENESIS; CELL VIABILITY; CHROMOSOME TRANSLOCATION; FUNCTIONAL GENOMICS; GENE FUSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE TARGETING; GENOME; HEMATOLOGIC MALIGNANCY; HUMAN; MOLECULARLY TARGETED THERAPY; MYELOPROLIFERATIVE NEOPLASM; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; POINT MUTATION; PRIORITY JOURNAL; REVIEW; RNA SPLICING;

EID: 84993660804     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620711403028     Document Type: Review

References (71)

1. Alizadeh A.A. Eisen M.B. Davis R.E. Ma C. Lossos I.S. Rosenwald A. et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503–511.
2. Augenlicht L.H. Wadler S. Corner G. Richards C. Ryan L. Multani A.S. et al. (1997) Low-level c-Myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res 57: 1769–1775.
3. Ben-Neriah Y. Daley G.Q. Mes-Masson A.M. Witte O.N. Baltimore D. (1986) The chronic myelogenous leukemia-specific P 210 protein is the product of the BCR / ABL hybrid gene. Science 233: 212–214.
4. Bos J.L. (1989) Ras oncogenes in human cancer: a review. Cancer Res 49: 4682–4689.
5. Brass A.L. Dykxhoorn D.M. Benita Y. Yan N. Engelman A. Xavier R.J. et al. (2008) Identification of host proteins required for HIV infection through a functional genomic screen. Science 319: 921–926.
6. Bric A. Miething C. Bialucha C.U. Scuoppo C. Zender L. Krasnitz A. et al. (2009) Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 16: 324–335.
7. Clark T.A. Schweitzer A.C. Chen T.X. Staples M.K. Lu G. Wang H. et al. (2007) Discovery of tissue-specific exons using comprehensive human exon microarrays. Genome Biol 8: R64–R64.
8. Cole M.D. (1986) The Myc oncogene: its role in transformation and differentiation. Annu Rev Genet 20: 361–384.
9. Collins S.J. Kubonishi I. Miyoshi I. Groudine M.T. (1984) Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells. Science 225: 72–74.
10. Daley G.Q. van Etten R.A. Baltimore D. (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247: 824–830.
11. Davis R.L. Konopka J.B. Witte O.N. (1985) Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties. Mol Cell Biol 5: 204–213.
12. de Risi J. Penland L. Brown P.O. Bittner M.L. Meltzer P.S. Ray M. et al. (1996) Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 14: 457–460.
13. Druker B.J. Guilhot F. O'Brien S.G. Gathmann I. Kantarjian H. Gattermann N. et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408–2417.
14. Druker B.J. Tamura S. Buchdunger E. Ohno S. Segal G.M. Fanning S. et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561–566.
15. Ebert B.L. Pretz J. Bosco J. Chang C.Y. Tamayo P. Galili N. et al. (2008) Identification of RPS 14 as a 5q- syndrome gene by RNA interference screen. Nature 451: 335–339.
16. Fitzgibbon J. Smith L.L. Raghavan M. Smith M.L. Debernardi S. Skoulakis S. et al. (2005) Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res 65: 9152–9154.
17. Frohling S. Scholl C. Levine R.L. Loriaux M. Boggon T.J. Bernard O.A. et al. (2007) Identification of driver and passenger mutations of FLT 3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 12 (6): 501–513.
18. Gale R.P. Canaani E. (1984) An 8-kilobase abl RNA transcript in chronic myelogenous leukemia. Proc Natl Acad Sci U S A 81: 5648–5652.
19. Gardina P.J. Clark T.A. Shimada B. Staples M.K. Yang Q. Veitch J. et al. (2006) Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics 7: 325–335.
20. George R.E. Sanda T. Hanna M. Frohling S. Luther W. 2nd Zhang J. et al. (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455: 975–978.
21. Gondek L.P. Tiu R. O'Keefe C.L. Sekeres M.A. Theil K.S. Maciejewski J.P. (2008) Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111: 1534–1542.
22. Goodman P.A. Wood C.M. Vassilev A. Mao C. Uckun F.M. (2001) Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia. Oncogene 20: 3969–3978.
23. Grosso A.R. Martins S. Carmo-Fonseca M. (2008) The emerging role of splicing factors in cancer. EMBO Rep 9: 1087–1093.
24. Hannon G.J. Rossi J.J. (2004) Unlocking the potential of the human genome with RNA interference. Nature 431: 371–378.
25. Heisterkamp N. Jenster G. ten Hoeve J. Zovich D. Pattengale P.K. Groffen J. (1990) Acute leukaemia in bcr / abl transgenic mice. Nature 344: 251–253.
26. Herman J.G. Baylin S.B. (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042–2054.
27. Hertzberg L. Vendramini E. Ganmore I. Cazzaniga G. Schmitz M. Chalker J. et al. (2010) Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF 2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 115: 1006–1017.
28. Hu G. Kim J. Xu Q. Leng Y. Orkin S.H. Elledge S.J. (2009) A genome-wide RNAi screen identifies a new transcriptional module required for self-renewal. Genes Dev 23: 837–848.
29. Irish J.M. Kotecha N. Nolan G.P. (2006) Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nat Rev Cancer 6: 146–155.
30. Kelliher M.A. McLaughlin J. Witte O.N. Rosenberg N. (1990) Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A 87: 6649–6653.
31. Lam L.T. Davis R.E. Ngo V.N. Lenz G. Wright G. Xu W. et al. (2008) Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen. Proc Natl Acad Sci U S A 105: 20798–20803.
32. Ley T.J. Mardis E.R. Ding L. Fulton B. McLellan M.D. Chen K. et al. (2008) DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456: 66–72.
33. Little C.D. Nau M.M. Carney D.N. Gazdar A.F. Minna J.D. (1983) Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194–196.
34. Loo J.C. Liu L. Hao A. Gao L. Agatep R. Shennan M. et al. (2003) Germline splicing mutations of CDKN2A predispose to melanoma. Oncogene 22: 6387–6394.
35. Loriaux M.M. Levine R.L. Tyner J.W. Frohling S. Scholl C. Stoffregen E.P. et al. (2008) High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 111: 4788–4796.
36. Luo J. Emanuele M.J. Li D. Creighton C.J. Schlabach M.R. Westbrook T.F. et al. (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137: 835–848.
37. Marcu K.B. Bossone S.A. Patel A.J. (1992) myc function and regulation. Annu Rev Biochem 61: 809–860.
38. Mariani-Costantini R. Escot C. Theillet C. Gentile A. Merlo G. Lidereau R. et al. (1988) In situ c-myc expression and genomic status of the c-myc locus in infiltrating ductal carcinomas of the breast. Cancer Res 48: 199–205.
39. Marioni J.C. Mason C.E. Mane S.M. Stephens M. Gilad Y. (2008) RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res 18: 1509–1517.
40. Mitelman F. Johansson B. Mertens F. (2007) The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 7: 233–245.
41. Mortazavi A. Williams B.A. McCue K. Schaeffer L. Wold B. (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5: 621–628.
42. Mullighan C.G. Collins-Underwood J.R. Phillips L.A. Loudin M.G. Liu W. Zhang J. et al. (2009) Rearrangement of CRLF 2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 41: 1243–1246.
43. Munzel P. Marx D. Kochel H. Schauer A. Bock K.W. (1991) Genomic alterations of the c-myc protooncogene in relation to the overexpression of c-erbB2 and Ki-67 in human breast and cervix carcinomas. J Cancer Res Clin Oncol 117: 603–607.
44. Ngo V.N. Davis R.E. Lamy L. Yu X. Zhao H. Lenz G. et al. (2006) A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441: 106–110.
45. Nowell P.C. Hungerford D.A. (1960) Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 25: 85–109.
46. Oh S.T. Simonds E.F. Jones C. Hale M.B. Goltsev Y. Gibbs K.D. Jr et al. (2010) Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 116: 988–992.
47. Paddison P.J. Silva J.M. Conklin D.S. Schlabach M. Li M. Aruleba S. et al. (2004) A resource for large-scale RNA-interference-based screens in mammals. Nature 428: 427–431.
48. Pinkel D. Segraves R. Sudar D. Clark S. Poole I. Kowbel D. et al. (1998) High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 20: 207–211.
49. Raghavan M. Lillington D.M. Skoulakis S. Debernardi S. Chaplin T. Foot N.J. et al. (2005) Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res 65: 375–378.
50. Ross D.T. Scherf U. Eisen M.B. Perou C.M. Rees C. Spellman P. et al. (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24: 227–235.
51. Rowley J.D. (1973) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243: 290–293.
52. Russell L.J. Capasso M. Vater I. Akasaka T. Bernard O.A. Calasanz M.J. et al. (2009) Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 114: 2688–2698.
53. Shtivelman E. Lifshitz B. Gale R.P. Canaani E. (1985) Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315: 550–554.
54. Silva J.M. Marran K. Parker J.S. Silva J. Golding M. Schlabach M.R. et al. (2008) Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 319: 617–620.
55. Silva J.M. Mizuno H. Brady A. Lucito R. Hannon G.J. (2004) RNA interference microarrays: high-throughput loss-of-function genetics in mammalian cells. Proc Natl Acad Sci U S A 101: 6548–6552.
56. Slamon D.J. Clark G.M. Wong S.G. Levin W.J. Ullrich A. McGuire W.L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182.
57. Sultan M. Schulz M.H. Richard H. Magen A. Klingenhoff A. Scherf M. et al. (2008) A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 321: 956–960.
58. Tomasson M.H. Xiang Z. Walgren R. Zhao Y. Kasai Y. Miner T. et al. (2008) Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 111: 4797–4808.
59. Tyner J.W. Deininger M.W. Loriaux M.M. Chang B.H. Gotlib J.R. Willis S.G. et al. (2009) RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci U S A 106: 8695–8700.
60. Tyner J.W. Walters D.K. Willis S.G. Luttropp M. Oost J. Loriaux M. et al. (2008) RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood 111: 2238–2245.
61. Walters D.K. Goss V.L. Stoffregen E.P. Gu T.L. Lee K. Nardone J. et al. (2006 a) Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. Leuk Res 30: 1097–1104.
62. Walters D.K. Mercher T. Gu T.L. O'Hare T. Tyner J.W. Loriaux M. et al. (2006 b) Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 10: 65–75.
63. Wang Z. Gerstein M. Snyder M. (2009) RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10: 57–63.
64. Westbrook T.F. Martin E.S. Schlabach M.R. Leng Y. Liang A.C. Feng B. et al. (2005) A genetic screen for candidate tumor suppressors identifies REST. Cell 121: 837–848.
65. Wheeler D.A. Srinivasan M. Egholm M. Shen Y. Chen L. McGuire A. et al. (2008) The complete genome of an individual by massively parallel DNA sequencing. Nature 452: 872–876.
66. Wulfkuhle J.D. Liotta L.A. Petricoin E.F. (2003) Proteomic applications for the early detection of cancer. Nat Rev Cancer 3: 267–275.
67. Xu Y. Fang F. Ludewig G. Jones G. Jones D. (2004) A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 23: 527–537.
68. Yoda A. Yoda Y. Chiaretti S. Bar-Natan M. Mani K. Rodig S.J. et al. (2010) Functional screening identifies CRLF 2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 107: 252–257.
69. Yokota J. Yamamoto T. Toyoshima K. Terada M. Sugimura T. Battifora H. et al. (1986) Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1 (8484): 765–767.
70. Zender L. Xue W. Zuber J. Semighini C.P. Krasnitz A. Ma B. et al. (2008) An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135: 852–864.
71. Zhao X. Li C. Paez J.G. Chin K. Janne P.A. Chen T.H. et al. (2004) An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res 64: 3060–3071.